Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing

LEVERKUSEN, Germany and BOSTON and NEW YORK and TORONTO and KYOTO, Japan, Dec. 12, 2016 - Bayer AG and Versant Ventures today announced the launch of BlueRock Therapeutics, a next-generation regenerative medicine company that plans to develop best-in-class induced pluripotent stem cell (iPSC) therapies to cure a range of diseases using an industry-leading platform. BlueRock Therapeutics will be led by a world-class team and has assembled its platform through a series of strategic partnerships with academia and industry.

For the Full Press Release Click Here